Blog

CD38-Based Quadruplets Take Center Stage in New Practice-Changing Myeloma Guidelines

Photo: Depositphotos

Jul 22, 2025, 11:31

CD38-Based Quadruplets Take Center Stage in New Practice-Changing Myeloma Guidelines

IACH shared on X about a recent paper by Wenming Chen et al. published in Clinical Hematology International:

“Just published in Clinical Hematology International

CD38-based quadruplets take center stage in new practice-changing myeloma guidelines!”

Title: Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group

Authors: Wenming Chen, Zhen Cai, James CS Chim, Wee Joo Chng, Juan Du, Chengcheng Fu, Ichiro Hanamura, Jian Hou, Jeffrey Shang-Yi Huang, Tadao Ishida, Aijun Liu, Vadim Ptushkin, Anastasiya Semenova, Naoki Takezako, Raymond Siu Ming Wong

Read the full article.

CD38-Based Quadruplets

More posts featuring Myeloma.

Aijun Liu Anastasiya Semenova cancer Chengcheng Fu Clinical Hematology International IACH Ichiro Hanamura James CS Chim Jeffrey Shang-Yi Huang Jian Hou Juan Du. Myeloma Naoki Takezako OncoDaily Oncology Raymond Siu Ming Wong Tadao Ishida Vadim Ptushkin Wee Joo Chng Wenming Chen Zhen Cai

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment

ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact

Ravi B. Parikh: Is Accelerated FDA Approval 23 Times Stronger than the Traditional?

Habib Nehmé: The U.S. Market Remains Elekta’s Most Strategic and Significant One

Mohamad Mohty: DREAMM-7 Marks a Step Forward in Relapsed Myeloma